Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose

Clinical Nephrology

Volumn 72, Issue 6, 2009, Pages 430-436

  Tanaka, H ^a   Oki, E ^a   Tsuruga, K ^a   Yashiro, T ^a   Hanada, I ^a   Ito, E ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Adolescents; Daily dose administration; Lupus nephritis; Maintenance therapy; Single; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; AMENORRHEA; ANTIBODY TITER; ARTICLE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT HEMOLYSIS TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; ONSET AGE; PEDIATRICS; PROTEIN URINE LEVEL; SCHOOL CHILD; SEROLOGY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; BIOPSY; COMPLEMENT C3; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71449095903     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNX06333     Document Type: Article

References (16)

1. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IVlupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19: 2001-2010.
2. Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptorhormone-binding function by tetratricopeptide repeat (TPR) proteins and immunosuppressive ligand FK506. Biochemistry. 2005; 44: 2030-2038.
3. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupuserythematosus with tacrolimus. Areport of three cases. Ann Rheum Dis. 1997; 56: 690-692.
4. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology. (Oxford) 2006; 45: 441-444.
5. Lai KN, Tang SCW, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology. (Carlton) 2005; 10: 180-188.
6. Maruyama M, Yamasaki Y, Sada K, Sarai A, Ujike K, Maeshima Y, Nakamura Y, Sugiyama H, Makino H. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol. 2006; 65: 276-279.
7. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005; 68: 813-817.
8. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009; 24: 15-20.
9. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus. 2000; 9: 445-450.
10. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus-(FK506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol. 2004; 62: 49-53.
11. Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V. Treatment of lupus nephritis with cyclosporine- An outcome analysis. Kidney Blood Press Res. 2007; 30: 124-128.
12. Suzuki K, Tsugawa K, Tanaka H. Tacrolimus for the treatment of focal segmental glomerulosclerosis resistant to cyclosporine A. Pediatr Nephrol. 2006; 21: 1913-1914.
13. Szeto CC, Kwan BCH, Lai FMM, Tam LS, Li EKM, Chow KM, Gang W, Li PKT. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. (Oxford) 2008; 47: 1678-1681.
14. Tanaka H, Oki E, Tsugawa K, Nonaka K, Suzuki K, Ito E. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus. 2007; 16: 896-900.
15. Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis: A clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008; 110: 73-79.
16. Tse KC, Lam MF, Tang SCW, Tang CSO, Chan TM. A pilot study on tacrolimus treatment inmembranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus. 2007; 16: 46-51.